Lisa Mathis

Summary

Affiliation: Food and Drug Administration
Country: USA

Publications

  1. ncbi Drug therapy in pediatrics: a developing field
    Lisa Mathis
    Office of New Drugs, FDA, Silver Spring, Maryland 20903, USA
    Dermatol Ther 22:257-61. 2009
  2. ncbi Safety monitoring of drugs granted exclusivity under the Best Pharmaceuticals for Children Act: what the FDA has learned
    L L Mathis
    Office of New Drugs, US Public Health Service, Silver Spring, Maryland, USA
    Clin Pharmacol Ther 82:133-4. 2007
  3. ncbi Improving pediatric dosing through pediatric initiatives: what we have learned
    William Rodriguez
    Food and Drug Administration, 5600 Fisher Lane, Parklawn Building, Room 13B 45, Rockville, MD 20850, USA
    Pediatrics 121:530-9. 2008

Collaborators

  • Rosemary Roberts
  • Shirley Murphy
  • William Rodriguez
  • Hari Cheryl Sachs
  • Jennifer Di Giacinto
  • Shiew-Mei Huang
  • Peter Lee
  • Veneeta Tandon
  • Debbie Avant
  • Sandra Suarez
  • Gerlie Gieser
  • Shiew Mei Huang
  • Dianne Murphy
  • Arzu Selen
  • Terrie Crescenzi
  • Ramana S Uppoor
  • Chandra Chaurasia

Detail Information

Publications3

  1. ncbi Drug therapy in pediatrics: a developing field
    Lisa Mathis
    Office of New Drugs, FDA, Silver Spring, Maryland 20903, USA
    Dermatol Ther 22:257-61. 2009
    ..With the new legislation and a better understanding of differences in the dose effectiveness and safety profiles of drugs in children when compared with adults, evidence-based treatment of pediatric patients is now possible...
  2. ncbi Safety monitoring of drugs granted exclusivity under the Best Pharmaceuticals for Children Act: what the FDA has learned
    L L Mathis
    Office of New Drugs, US Public Health Service, Silver Spring, Maryland, USA
    Clin Pharmacol Ther 82:133-4. 2007
    ..In most of the cases, no unexpected adverse events were reported in the pediatric population; however, in some cases, this focused safety review provided information important to the safety of medication use in children...
  3. ncbi Improving pediatric dosing through pediatric initiatives: what we have learned
    William Rodriguez
    Food and Drug Administration, 5600 Fisher Lane, Parklawn Building, Room 13B 45, Rockville, MD 20850, USA
    Pediatrics 121:530-9. 2008
    ..The goal was to review the impact of pediatric drug studies, as measured by the improvement in pediatric dosing and other pertinent information captured in the drug labeling...